Eric K. Outwater, MD

His research interests are primarily in genitourinary and gynecologic MRI. He has been the primary facilitator of physician education in RECIST measurements in the department and serves as medical director for the Image Response Assessment Team (IRAT) Core facility.  He has been instrumental in securing funding for the IRAT for clinical trials using tumor metrics at Moffitt.

• Outwater EK. Imaging of the liver for hepatocellular cancer. Cancer Control. 2010 Apr;17(1):72-82. Pubmedid: 20404790.
• Raman SS, Leary C, Bluemke DA, Amendola M, Sahani D, McTavish JD, Brody J, Outwater E, Mitchell D, Sheafor DH, Fidler J, Francis IR, Semelka RC, Shamsi K, Gschwend S, Feldman DR, Breuer J. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr. 2010 Mar-Apr;34(2):163-172. Pubmedid: 20351497. Pmcid: PMC3036163.
• Li Z, Graff C, Gmitro AF, Squire SW, Bilgin A, Outwater EK, Altbach MI. Rapid water and lipid imaging with T2 mapping using a radial IDEAL-GRASE technique. Magn Reson Med. 2009 Jun;61(6):1415-1424. Pubmedid: 19353651. Pmcid: PMC2747511.
• Knowles NG, Smith DL, Outwater EK. MRI diagnosis of brown tumor based on magnetic susceptibility. J Magn Reson Imaging. 2008 Sep;28(3):759-761. Pubmedid: 18777537.
• Chen Z, Wang Z, Lohman T, Heymsfield SB, Outwater E, Nicholas JS, Bassford T, LaCroix A, Sherrill D, Punyanitya M, Wu G, Going S. Dual-energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in older women. J Nutr. 2007 Dec;137(12):2775-2780. Pubmedid: 18029498.
• Gigena M, Villar HV, Knowles NG, Cunningham JT, Outwater EK, Leon LR. Antegrade bowel intussusception after remote Whipple and Puestow procedures for treatment of pancreas divisum. World J Gastroenterol. 2007 Nov;13(44):5954-5956. Pubmedid: 17990363.
• Shin SL, Outwater EK. Benign large cell calcifying Sertoli cell tumor of the testis in a prepubescent patient. AJR Am J Roentgenol. 2007 Aug;189(2):W65-W66. Pubmedid: 17646440.
• Erly WK, Oh ES, Outwater EK. The utility of in-phase/opposed-phase imaging in differentiating malignancy from acute benign compression fractures of the spine. AJNR Am J Neuroradiol. 2006 June;27(6):1183-1188. Pubmedid: 16775260.
• Saini S, Sharma R, Baron RL, Turner DA, Ros PR, Hahn PF, Small WC, Delange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clin Radiol. 2000 Sep;55(9):690-695. Pubmedid: 10988047.
• Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, Robinson RA, Amorosa JK, Mammone JF, Outwater EK. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging. 1999 Sep;10(3):468-473. Pubmedid: 10508310.
• Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF, Rubin DL, Zelch JV, Kuhlman JE, Outwater EK, Weinreb JC, Brown JJ, de Lange EE, Woodward PJ, Arildsen R, Foster GS, Runge VM, Aisen AM, Muroff LR, Thoeni RF, Parisky YR, Tanenbaum LN, Totterman S, Herfkens RJ, Knudsen J, Bernardino ME. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. J Magn Reson Imaging. 1999 Jul;10(1):15-24. Pubmedid: 10398973.
• Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK, Morris M, Lucas M. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J Magn Reson Imaging. 1999 Feb;9(2):291-294. Pubmedid: 10077027.
• Mitchell DG, Outwater EK, Matteucci T, Rubin DL, Chezmar JL, Saini S. Adrenal gland enhancement at MR imaging with Mn-DPDP. Radiology. 1995 Mar;194(3):783-787. Pubmedid: 7862979.